NASDAQ:ELYM Eliem Therapeutics - ELYM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.85 0.00 (0.00%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.85▼$3.8550-Day Range$2.48▼$4.6452-Week Range$2.36▼$11.51Volume190 shsAverage Volume16,242 shsMarket Capitalization$102.29 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Eliem Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside55.8% Upside$6.00 Price TargetShort InterestHealthy0.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.03Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.88) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector669th out of 1,055 stocksPharmaceutical Preparations Industry339th out of 519 stocks 3.3 Analyst's Opinion Consensus RatingEliem Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Eliem Therapeutics has a forecasted upside of 55.8% from its current price of $3.85.Amount of Analyst CoverageEliem Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.12% of the float of Eliem Therapeutics has been sold short.Short Interest Ratio / Days to CoverEliem Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eliem Therapeutics has recently increased by 81.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEliem Therapeutics does not currently pay a dividend.Dividend GrowthEliem Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELYM. Previous Next 1.1 News and Social Media Coverage News SentimentEliem Therapeutics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Eliem Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ELYM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eliem Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Eliem Therapeutics is held by insiders.Percentage Held by Institutions63.29% of the stock of Eliem Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Eliem Therapeutics are expected to grow in the coming year, from ($1.88) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eliem Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eliem Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEliem Therapeutics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eliem Therapeutics (NASDAQ:ELYM) StockEliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.Read More Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ELYM Stock News HeadlinesNovember 30, 2022 | finance.yahoo.comEliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual ConferenceNovember 14, 2022 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports Third Quarter Financial and Business HighlightsJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 12, 2022 | finance.yahoo.comIs Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth?November 8, 2022 | finance.yahoo.comEliem Therapeutics to Participate at Two Upcoming Investor ConferencesAugust 18, 2022 | seekingalpha.comEliem Therapeutics (ELYM) Investor Presentation - SlideshowAugust 15, 2022 | msn.comEliem Therapeutics: Q2 Earnings InsightsAugust 15, 2022 | finance.yahoo.comEliem Therapeutics Reports Second Quarter Financial and Business HighlightsJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…August 2, 2022 | nasdaq.comEliem Therapeutics Discontinues ETX-810 Program As Phase 2a Trial In Sciatica FailsAugust 2, 2022 | finance.yahoo.comEliem Therapeutics Shares Fall On Lower Back Pain Trial SetbackAugust 2, 2022 | finance.yahoo.comEliem's stock slides 20% after saying it will discontinue development of pain treatmentAugust 2, 2022 | marketwatch.comEliem Therapeutics Scraps Lead Candidate After Study Failure >ELYMAugust 2, 2022 | finance.yahoo.comEliem Therapeutics Provides ETX-810 Program UpdateJuly 11, 2022 | markets.businessinsider.comSVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To KnowJuly 7, 2022 | finance.yahoo.comEliem Therapeutics to Host Virtual Investor Event on July 21, 2022June 27, 2022 | finance.yahoo.comEliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)May 17, 2022 | seekingalpha.comHarpoon Therapeutics, Grove top healthcare gainers; Chimerix, Eliem lead losers' packMay 16, 2022 | finance.yahoo.comEliem Therapeutics Reports First Quarter Financial and Business HighlightsMay 9, 2022 | finance.yahoo.comEliem Therapeutics, Inc. (ELYM) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 28, 2022 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Eliem Therapeutics, Inc. - ELYMApril 26, 2022 | benzinga.comGuggenheim Downgrades Eliem Therapeutics to NeutralApril 25, 2022 | markets.businessinsider.comMid-Afternoon Market Update: Nasdaq Rises 70 Points; Eliem Therapeutics Shares SlideApril 25, 2022 | seekingalpha.comEliem stock tanks 54% as ETX-810 fails in diabetic pain study; delays enrollment in depression trial of ETX-155April 25, 2022 | marketwatch.comEliem Therapeutics Shares Plummet After Double Pipeline Setbacks >ELYMApril 25, 2022 | finance.yahoo.comEliem Provides Update on ETX-810 and ETX-155 Clinical ProgramsApril 25, 2022 | marketwatch.comEliem Therapeutics Reports Setback in ETX-810, ETX-155 >ELYMSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ELYM Company Calendar Last Earnings11/14/2022Today1/28/2023Next Earnings (Estimated)3/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ELYM CUSIPN/A CIK1768446 Webwww.eliemtx.com Phone425-276-2300FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+55.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.38% Return on Assets-29.99% Debt Debt-to-Equity RatioN/A Current Ratio21.21 Quick Ratio21.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.30 per share Price / Book0.61Miscellaneous Outstanding Shares26,570,000Free Float25,319,000Market Cap$102.29 million OptionableNot Optionable Beta0.56 Key ExecutivesMr. Robert W. Azelby M.B.A. (Age 54)Pres, CEO & Director Comp: $941.6kMs. Erin M. Lavelle (Age 45)Exec. VP, COO & CFO Comp: $681.79kDr. Valerie Morisset Ph.D. (Age 52)Chief Scientific Officer and Exec. VP of R&D Comp: $557.32kMr. James B. Bucher J.D. (Age 56)Exec. VP, Gen. Counsel & Sec. Ms. Jo Palmer-Phillips Ph.D.Chief Devel. OfficerDr. Mark Versavel M.B.A. (Age 63)M.D., MBA, Ph.D., Interim Chief Medical Officer Ms. Susan Franks M.S.Sr. VP & Head of Regulatory AffairsMore ExecutivesKey CompetitorsFortress BiotechNASDAQ:FBIOEton PharmaceuticalsNASDAQ:ETONTheratechnologiesNASDAQ:THTXSeelos TherapeuticsNASDAQ:SEELReviva PharmaceuticalsNASDAQ:RVPHView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 3,624 shares on 11/15/2022Ownership: 0.044%Atom Investors LPBought 40,765 shares on 11/8/2022Ownership: 0.252%View All Institutional Transactions ELYM Stock - Frequently Asked Questions Should I buy or sell Eliem Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eliem Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ELYM shares. View ELYM analyst ratings or view top-rated stocks. What is Eliem Therapeutics' stock price forecast for 2023? 3 equities research analysts have issued 1-year price objectives for Eliem Therapeutics' stock. Their ELYM share price forecasts range from $4.00 to $8.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 55.8% from the stock's current price. View analysts price targets for ELYM or view top-rated stocks among Wall Street analysts. How have ELYM shares performed in 2023? Eliem Therapeutics' stock was trading at $3.67 on January 1st, 2023. Since then, ELYM shares have increased by 4.9% and is now trading at $3.85. View the best growth stocks for 2023 here. Are investors shorting Eliem Therapeutics? Eliem Therapeutics saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 21,000 shares, an increase of 81.0% from the December 31st total of 11,600 shares. Based on an average daily volume of 7,000 shares, the short-interest ratio is presently 3.0 days. Approximately 0.1% of the company's shares are sold short. View Eliem Therapeutics' Short Interest. When is Eliem Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023. View our ELYM earnings forecast. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) released its quarterly earnings results on Monday, November, 14th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.05. When did Eliem Therapeutics IPO? (ELYM) raised $75 million in an initial public offering on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO. What is Eliem Therapeutics' stock symbol? Eliem Therapeutics trades on the NASDAQ under the ticker symbol "ELYM." How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Eliem Therapeutics' stock price today? One share of ELYM stock can currently be purchased for approximately $3.85. How much money does Eliem Therapeutics make? Eliem Therapeutics (NASDAQ:ELYM) has a market capitalization of $102.29 million. The company earns $-47,480,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. How can I contact Eliem Therapeutics? The official website for the company is www.eliemtx.com. The company can be reached via phone at 425-276-2300 or via email at investorrelations@eliemtx.com. This page (NASDAQ:ELYM) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.